Emcure Pharmaceuticals Ltd delivered robust Q4 FY26 results on May 5, with net profit surging 29% year-on-year to ₹243 crore from ₹189 crore in the previous year. According to reports from CNBC TV18, revenue increased 16.7% to ₹2,469.7 crore compared to ₹2,116.2 crore in the year-ago period, reflecting healthy traction across key markets. EBITDA grew 19.2% to ₹479.5 crore, while margins improved marginally to 19.4% from 19% a year earlier, demonstrating operational efficiency gains. The company's international business remained the key growth driver, with sales rising 25.7% YoY to ₹1,493 crore, supported by base business ramp-up and new product launches, while domestic sales came in at ₹977 crore, up 5.2% YoY.
Despite the strong financial performance, the stock reacted negatively, falling over 5% in intraday trade on the NSE after hitting a 52-week high of ₹1,830 earlier in the session. According to latest market data, the stock touched an intraday high of ₹1,666.00 and an intraday low of ₹1,624.00, with trading volumes of 63,344 shares compared to its five-day average of 257,445 shares, representing a 75.40% decrease in trading volume. The negative market reaction occurred despite the company's strong bottom-line growth, indicating investor concerns about other factors or broader market sentiment.
Management highlighted strong execution in the first year of its five-year strategic plan, with international markets driving growth and continued focus on complex injectables and biosimilars expected to support long-term expansion. As reported by CNBC TV18, the company's strategic focus on complex injectables and biosimilars positions it well for sustained growth in the pharmaceutical sector, with management expressing confidence in achieving long-term expansion goals through this strategic approach. The company also approved the re-appointment of Dr Mukund Gurjar as Whole-time Director for one year from August 2026, and Satish Mehta as Managing Director for five years from April 2027.
